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ABSTRACT
Background: Inhaled corticosteroids (ICSs) have become widely used in asthma management during preg-
nancy since the publication of the NIH report Management of Asthma during Pregnancy in 1993. In the current
study, the usefulness and safety of ICSs in the treatment of pregnant women with asthma were investigated.
Methods: Of 11,358 women who delivered in our hospital between January 1987 and December 2003, 592
women had asthma. Their midwifery records, delivery records, and clinical charts retained in the outpatient
clinic of the internal medicine department were reviewed to identify treatments provided, pregnancydelivery
course, and possible perinatal abnormalities. On the basis of these data, the usefulness and safety of ICSs
were retrospectively investigated.
Results: The percentage of pregnant women with asthma receiving asthma treatment was 17.5% from 1987
to 1989, 32.7% from 1990 to 1994, 43.8% from 1995 to 1999, and 40.7% from 2000 to 2003. Among those
treated, the proportion treated with ICSs showed an increase (0% from 1987 to 1989, 10.0% from 1990 to
1994, 55.3% from 1995 to 1999, and 83.3% from 2000 to 2003). Intrapartum asthma attacks occurred in 1.38%
of the asthma patients from 1995 to 1999, while there was no such occurrence in 2000 or later. In the untreated
patients, the incidence of perinatal abnormalities remained unchanged with the guideline publication (31.6%
before and 31.3% after). In contrast, the incidence of perinatal abnormalities in the treated patients decreased
from 59.6% to 26.2% with the guideline publication. The incidence of perinatal abnormality among the treated
was compared between the ICS therapy and non-ICS therapy groups. No difference was observed between
the two groups from 1987 to 1994, but from 1995 to 2003, the total incidence of perinatal abnormalities was sig-
nificantly higher in the non-ICS group.
Conclusions: ICSs can be considered to be safe and useful for the prevention of asthma attacks during preg-
nancy and for decreasing perinatal abnormalities．
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INTRODUCTION
Frequent bronchial asthma attacks are associated
with premature delivery, preeclampsia, placenta pre-
via , and caesarean section in pregnant women . 1,2
Schatz, who reviewed recent literature data, has dem-
onstrated lower incidences of perinatal fetal deaths,
premature deliveries, and low birth weight newborns
in women treated by asthma specialists than in those
treated by non-specialists , and stressed the impor-
tance of asthma control during pregnancy. 3 Green-
berger and Patterson reported frequent low birth
weight newborns and intrauterine growth retardation
in pregnant women with asthma attacks.4 Schatz et al.
demonstrated no difference in the incidence of peri-
natal fetal deaths, low birth weight newborns, or in-
trauterine growth retardation between healthy
women and women receiving aggressive anti-
asthmatic therapy consisting mainly of ICSs.5
ICSs have come into wide use in asthma manage-
ment during pregnancy since the publication of Man-
agement of Asthma during Pregnancy in 1993.6 Cur-
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Table 1 Patient profile
1995―2003
n = 399
1987―94
n = 193
30.2 ± 4.428.9 ± 4.0Mean age (years)
Asthma type
352169　atopy
4724　non-atopy
Asthma severity
101　severe
314　moderate
12752　mild
231136　no treatment
n = 168n = 57Therapy
113　oral steroid
1178　inhaled steroid
5122　oral theophyline
154　oral β-agonist
3823　inhaled β alone
rently, more ICSs are available, and more and more
reports regarding the usefulness and safety of ICS
therapy in pregnant women are being published. Ac-
cording to the Pregnancy Risk Categories , which
were established by the US Food and Drug Admini-
stration (FDA) to indicate a drug’s potential for caus-
ing teratogenicity, ICSs are classified as category B
or C, i.e., the safety of ICSs is uncertain. In the cur-
rent study, the usefulness and safety of ICSs in the
treatment of pregnant women with asthma were in-
vestigated.
METHODS
Of 11,358 women who delivered in our hospital be-
tween January 1987 and December 2003, 592 women
had asthma (mean age:29.8 ± 4.4 years;atopic, 521 pa-
tients ; non- atopic, 71 ; severe, 11 ; moderate, 35 ;
mild, 179 ; asymptomaticuntreated, 367). Any mid-
wifery records, delivery records, and clinical charts
retained in the outpatient clinic of internal medicine,
were reviewed to identify treatments provided, preg-
nancydelivery course, and possible perinatal abnor-
malities. On the basis of these data, the usefulness
and safety of ICSs were investigated. In our hospital,
ICSs have been used more commonly in pregnant
women with asthma since around 1995 in response to
the publication of Management of Asthma during
Pregnancy. Therefore, the incidence of perinatal ab-
normalities by treatment was compared by chi-square
test between women treated before 1995 and those
treated in 1995 or later to investigate the possible as-
sociation between anti-asthma treatment and perina-
tal abnormalities (Table 1).
RESULTS
The proportion of asthmatic pregnant women to all
pregnant women has steadily increased year by year
(Fig. 1). In the current study, pregnant women with
asthma were divided into two groups:women who
had been asymptomatic and untreated for at least one
year (untreated group) and women who were receiv-
ing antiasthma therapy, including inhaled β-agonists
alone (treatment group). The percentage of pregnant
women with asthma receiving asthma treatment was
17.5% from 1987 to 1989, 32.7% from 1990 to 1994,
43.8% from 1995 to 1999, and 40.7% from 2000 to 2003
(Fig. 2). Among the treated, the proportion of women
treated with ICSs showed an increasing tendency
(0%, 10.0%, 55.3%, and 83.3%, respectively), whereas a
decreasing tendency was observed in the proportion
of women treated with oral theophylline ( 33.3% ,
40.0%, 34.0%, 22.2%, respectively). The proportion of
women treated with inhaled β-agonist alone also de-
creased (66.7%, 38.0%, 29.1%, 11.1% , respectively ) .
The percentage of women treated with oral corti-
costeroids was 0%, 6.0%, 2.9%, and 11.1%, while the
percentage of women regularly taking oral β-agonists
was 0%, 8.0%, 3.9%, and 15.3%, respectively (Fig. 3).
We evaluated the intrapartum asthma attacks
based on the data from midwifery records and deliv-
ery records. The percentage of pregnant women with
asthma experiencing intrapartum asthma attacks was
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Fig. 3  Trends of asthma treatment during pregnancy. The 
proportion of women treated with ICSs showed an increase, 
whereas a decrease was observed in the proportion of wo-
men treated with oral theophyline. The proportion of women 
treated with inhaled β-agonist alone has decreased. 
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Table 2
1995―20031987―94
Treatment (+)
n = 168
Treatment (-)
n = 231
Treatment (+)
n = 57
Treatment (-)
n = 136
 0.6% 0% 0% 0.7%Fetal death
 4.8% 3.0% 3.5% 3.7%Fetal distress
 0% 0% 0% 1.5%Malformation
 3.6% 2.2% 5.3% 5.9%Premature delivery
 8.9% 15.2% ＊ 3.5% 9.6%Weak labor
 0.6% 0% 0% 0%Early rupture of membrane
 6.0% 3.5% 1.8% 2.2%Premature rupture of memb.
 0% 0% 0% 1.5%Polyhydramnios
 0% 0% 1.8% 1.5%Toxemia of pregnancy
 0% 0.9% 1.8% 2.9%Prolonged labor
 0% 0% 1.8% 0.7%Atonic bleeding
 6.0% 7.8% 1.8% 5.1%Cesarean section
Comparison of perinatal abnormalities between the treated group and the untreated group. 
＊p < 0.05 
1.38% (3217) from 1995 to 1999, while there was no
such encounter from 2000 to 2003. These three
women with intrapartum asthma attacks had been
treated with inhaled β-agonists alone. Women treated
with ICSs did not have any intrapartum asthma at-
tacks. The percentage of women who received drip
infusion therapy for asthma attacks during pregnancy
was 24.0% in 1998, 25.6% in 1999, 6.0% in 2000, 11.4%
in 2001, 14.6% in 2002, and 4.3% in 2003, showing a
decreasing tendency in recent years resulting from
the regular use of ICSs. The data before 1998 could
not be obtained due to the disposal of clinical charts．
Pregnancy or delivery-associated abnormalities
(perinatal abnormalities), including intrauterine fetal
death, fetal distress, malformation, premature deliv-
ery, weak labor, early rupture of the membranes, pre-
mature rupture of the membranes, polyhydramnios,
toxemia of pregnancy, prolonged labor, atonic bleed-
ing , and caesarean section , were observed in 172
(30.8%) of the total 592 pregnant women with asthma.
Perinatal abnormalities occurred in 119 (32.4%) of 367
women with asymptomaticuntreated asthma, in 45
(25.1%) of 179 women with mild asthma, in 4 (11.4%)
of 35 women with moderate asthma, and in 4 (36.4%)
of 11 women with severe asthma, indicating a lower
incidence in moderate cases than in untreated and se-
vere cases. The incidence of perinatal abnormalities
was 23.2% (27125) in women treated with ICS, 27.4%
(2073) in women treated with oral theophylline, and
26.2% ( 1661 ) in women treated with inhaled β-
agonists alone, showing no differences between these
drugs (Fig. 4). The incidence with each ICS drug was
24.2% ( 2291 ) for beclomethasone dipropionate
(BDP), 15.0% (320) for fluticasone propionate (FP),
and 28.6% (27) for budesonide (BUD), showing less
frequent perinatal abnormalities with FP than with
BDP．
The incidence of each perinatal abnormality was
compared between the treated and untreated groups
to determine a possible association between an-
tiasthma therapy and perinatal abnormalities. No dif-
ference was observed between the two groups from
1987 to 1994. From 1995 to 2003, the incidence of fe-
tal distress, premature delivery, and premature rup-
ture of the membranes was higher, though not sig-
nificant, in the treated group. In the untreated group,
weak labor occurred more frequently (p < 0.05)(Ta-
ble 2). In the untreated group, the total incidence of
perinatal abnormalities showed no difference be-
tween the two periods (1987―1994 : 31.6% ; 1995―
2003 : 31.3%) . In the treated group , on the other
hand, the incidence decreased from 59.6% in 1987―
1994 to 26.2% in 1995―2003 (p < 0.01)(Table 3). The
incidence of perinatal abnormality was compared be-
tween the ICS therapy group and non-ICS therapy
group. No difference was observed between the two
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Fig. 4  The incidence of perinatal abnormalities in relation 
to therapeutic grade and therapeutic drugs. 
ICS: inhaled corticosteroid,  ＊p < 0.01,＊＊p < 0.05
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Table 3
Treatment (-)
1995―2003
n = 231
1987―94
n = 136
31.3%31.6%
Total Perinatal
Abnormalities (%)
Treatment (+)
1995―2003
n = 168
1987―94
n = 57
26.2%＊59.6%
Total Perinatal
Abnormalities (%)
Comparison of the total incidence of perinatal abnormalities 
between two periods (1987―94 and 1995―2005).
＊p < 0.01
groups in 1987―1994. In 1995―2003, the total inci-
dence of perinatal abnormalities was higher in the
non-ICS group (p < 0.10)(Table 4). The comparison of
the incidence of each perinatal abnormality in women
receiving ICS and non-ICS therapy showed more fre-
quent premature rupture of the membrane in women
on ICS therapy in 1995 or later, when the use of ICSs
became more common (p < 0.10). Weak labor and
early rupture of the membranes occurred less fre-
quently in women on ICS therapy (p < 0.05, p < 0.01,
respectively)(Table 4).
DISCUSSION
In the West , approximately 1% of pregnant women
have bronchial asthma . 7 A number of pregnant
women with asthma are referred to our hospital . It
seems that the morbidity of asthma in pregnant
women is increasing year by year. ICSs have become
widely used in asthma management during preg-
nancy since the publication of the Management of
Asthma during Pregnancy report in 1993. Today, a lot
of reports regarding the safety of ICSs are available.
These drugs include BDP,8,9 which has been used for
years, and BUD,10,11 which is used more commonly.
Safety reports regarding FP are also gradually in-
creasing with its popularization. In the current study,
ICSs were prescribed to 55.3% of pregnant women
with asthma treated from 1995 to 1999, and the fre-
quency of ICS therapy became 83.3% in 2000 or later.
Three intrapartum asthma attacks were encountered
from 1995 to 1999, while there was no attack from
2000 to 2003. These three women had been treated
with inhaled β-agonists alone, and no patient receiv-
ing ICSs therapy had an intrapartum asthma attack. A
decreasing tendency of drip infusion therapy for
asthma attacks during pregnancy was observed in re-
cent years, likely resulting from the increase of ICS
therapy. Thus it seems that ICS therapy is useful for
pregnant women with asthma．
The incidence of perinatal abnormalities in terms
of treatment provided (no treatment, mild, moderate,
severe) was compared to investigate the possible as-
sociation between anti-asthma therapy and perinatal
abnormalities . There was no evidence indicating
more frequent perinatal abnormalities in terms of
treatment provided. Equally, Dombrowski et al. dem-
onstrated that there is no difference in maternal com-
plications except for caesarean delivery between
moderatesevere asthma and healthy controls . 12
Comparisons between ICSs and theophylline6,13 or in-
haled β-agonists,6,14 showed no difference in the inci-
dence of perinatal abnormalities. The comparison be-
tween ICS drugs exhibited less frequent perinatal ab-
normalities with FP than with BDP. For BUD, which
is not yet used widely as it became available recently
in Japan, the assessment is difficult. The lower inci-
dence of perinatal abnormalities with FP could be at-
tributable partly to a smaller biological effect com-
pared with BDP due to a lower gastrointestinal
bioavailability (only 1% vs. 15―20% for BDP) and due
to a greater first-pass effect in the liver (99% vs. 70%
for BDP) even if the entire dose is absorbed from the
gastrointestinal tract. BUD is now widely used in the
West because of its higher safety due to a lower gas-
trointestinal bioavailability compared with BDP. The
safety of BUD in the Japanese population remains to
be assessed．
In untreated patients, the incidence of perinatal ab-
normalities remained unchanged after popularization
of the guideline (approximately 31%). In contrast, the
incidence of perinatal abnormalities decreased signifi-
cantly from 59.6% before popularization of the guide-
line. These findings suggest that before populariza-
tion of the guideline, insufficient treatment and con-
cerns about the use of antiasthmatic drugs during
pregnancy as well as lack of knowledge about asthma
resulted in poor asthma management . However ,
popularization of the guideline has facilitated provi-
sion of ICSs and other effective anti-asthma therapies,
which has led to fewer asthma attacks and resulted in
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Table 4
1995―20031987―94
Inhaled steroid (-)
n = 58
Inhaled steroid (+)
n = 117
Inhaled steroid (-)
n = 42
Inhaled steroid (+)
n = 8
 1.7% 0% 0% 0%Fetal death
 5.2% 4.3% 4.8% 0%Fetal distress
 0% 0% 0% 0%Malformation
 5.2% 2.6% 7.0% 0%Premature delivery
 15.5% ＊＊ 5.1% 4.8% 0%Weak labor
 10.3% ＊ 0% 0% 0%Early rupture of membrane 
 1.7% 7.7% ＊＊＊ 0% 12.5%Premature rupture of memb. 
 0% 0% 0% 0%Polyhydramnios
 0% 0% 2.4% 0%Toxemia of pregnancy
 0% 0% 2.4% 0%Prolonged labor
 0% 0% 2.4% 0%Atonic bleeding
 5.2% 6.0% 2.4% 0%Cesarean section
 31.0% ＊＊＊ 20.5% 19.0% 12.5%Total (%)
Comparison of perinatal abnormalities between the ICS therapy group and non-ICS therapy group.
ICS: inhaled corticosteroid  ＊p < 0.01, ＊＊p < 0.05, ＊＊＊p < 0.10
less frequent perinatal abnormalities. The incidence
of perinatal abnormalities was compared between pa-
tients treated with ICSs and those treated with non-
inhaled corticosteroids in 1995 or later, the period in
which the use of ICSs in pregnant women became
more widespread. From 1995 to 2003, the incidence
of total perinatal abnormalities was higher in the non-
ICS group. Frequent bronchial asthma attacks are as-
sociated with premature delivery, preeclampsia, pla-
centa previa , and caesarean section in pregnant
women. In the current study, these were not found to
occur . The incidence of all perinatal abnormalities
was comparable between the two treatment groups
with the exception that the incidence of premature
rupture of the membranes was slightly higher in
women treated with ICSs than in those treated with
drugs other than inhaled corticosteroids. The major-
ity of cases of premature rupture of the membranes
are attributable to vaginitis or salpingitis spreading to
the fetal membranes. However, none of the women
who experienced premature rupture of the mem-
branes had any systemic problems or higher suscep-
tibility to infection due to ICS therapy. In general, the
incidence of premature rupture of the membranes is
reported to be 10.7―22.4%.15-19 In the current study,
premature rupture of the membranes occurred more
frequently in women treated with ICSs from 1995 to
2003. However, the incidence (7.7%) was not greater
than the incidence in the literature in pregnant
women with asthma or in pregnant women treated
with ICSs. Therefore, we concluded that ICSs were
safe for pregnant women with asthma．
Prevention of asthma attacks is the most important
in asthma management during pregnancy. ICSs,
which are effective in achieving this goal, can be con-
sidered useful and safe. In order to resolve any safety
concerns about the use of an anti-asthma drug during
pregnancy, enthusiastic patient education on asthma
therapy starting at the stage in which a woman is
planning to become pregnant may be critical. Asthma
management with PEF is also important for achieving
this goal.6 In our hospital, we have succeeded in pa-
tient education by distributing materials we prepared
for education of pregnant women with asthma.20 Fur-
ther assessment is necessary to determine the safety
of high-dose ICSs and the maximum permissible
dose in pregnant women．
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